Medicine and Dentistry
Adult
7%
Amphotericin
18%
Amphotericin B Lipid Complex
11%
Analysis
13%
Antigen
36%
Antiretroviral Therapy
16%
Cells
9%
Cerebrospinal Fluid
26%
Clinical Trial
19%
Cluster Randomized Trial
5%
Combination Therapy
24%
Cost-Effectiveness Analysis
33%
COVID-19
10%
Cryptococcal Meningitis
55%
Culture
9%
Death
8%
Diagnosis
28%
Disease
18%
Drug Megadose
15%
Fecal Microbiota Transplantation
5%
Fluconazole
20%
Health
8%
Health Care Cost
28%
Human Immunodeficiency Virus
74%
Infection
17%
Laboratory
7%
Meningitis
23%
Monitoring
5%
Monotherapy
7%
Mortality
17%
Outpatient
15%
Patient
20%
Person
36%
Physician
5%
Plasma
6%
Quality Adjusted Life Year
5%
Randomized Clinical Trial
6%
Randomized Controlled Trial
9%
Screening
25%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Survival
11%
Symptom
5%
Systematic Review
5%
Therapeutic Procedure
43%
Tuberculosis
8%
Tuberculous Meningitis
11%
Virus Infection
5%
Immunology and Microbiology
Antigen
70%
Blood Plasma
8%
CD4
18%
CD4 Lymphocyte Count
12%
Cells
17%
Cerebrospinal Fluid
34%
Chloroquine
5%
COVID-19
32%
Cryptococcus neoformans
6%
Cytokine
6%
Cytomegalovirus
5%
Flow
25%
Human Immunodeficiency Virus
75%
Hydroxychloroquine
23%
Immune Response
6%
Incidence
7%
Internet
5%
Meningitis
100%
Mental Health
6%
Mortality
28%
Pregnancy
9%
Prevalence
13%
Puerperium
5%
Sample
8%
Screening
18%
Severe Acute Respiratory Syndrome Coronavirus 2
17%
Survival
12%
Time
6%
Titer
11%
Tuberculous Meningitis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
7%
Amphotericin
21%
Amphotericin B
7%
Amphotericin B Lipid Complex
13%
Antigen
36%
Clinical Trial
8%
Cohort Study
6%
Coronavirinae
19%
Cryptococcal Meningitis
50%
Cryptococcosis
6%
Death
7%
Diseases
25%
Filobasidiella
8%
Fluconazole
40%
Flucytosine
7%
HIV
44%
Hydroxychloroquine
28%
Infection
16%
Meningitis
28%
Monotherapy
7%
Mortality
16%
Placebo
8%
Randomized Clinical Trial
11%
SARS Coronavirus
10%
Sertraline
6%
Survival
14%
Tuberculous Meningitis
9%